Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2018 16:29 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6
August 01, 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
July 12, 2018 07:00 ET
|
Zogenix, Inc.
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2018 16:32 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Welcomes New Global Chief Commercial Officer
July 02, 2018 08:00 ET
|
Zogenix, Inc.
Ashish Sagrolikar Brings Over 25 Years of Global Pharmaceutical Sales, Marketing and Operations Experience to Zogenix EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2018 16:24 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
May 14, 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
May 09, 2018 16:01 ET
|
Zogenix, Inc.
Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndromeStudy 1504 fully enrolled...
Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
May 04, 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2018 17:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...